Volagidemab

BIOLOGICAL2 trials

Sponsors

University of California, San Diego, REMD Biotherapeutics, Inc.

Conditions

Type 1 DiabetesType 1 Diabetes Mellitus

Phase 1

Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

Active, not recruitingNCT05696366

University of California, San DiegoType 1 Diabetes

Start: 2024-09-09End: 2028-01-01Target: 24Updated: 2026-06-15

Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab

CompletedNCT06272695

REMD Biotherapeutics, Inc.Type 1 Diabetes Mellitus

Start: 2024-02-15End: 2025-02-01Updated: 2025-06-03